- Home
- TSBK vs RIGL Comparison
TSBK vs RIGL Comparison
Compare TSBK & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSBK | RIGL |
|---|---|---|
| Founded | 1915 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.5M | 537.6M |
| IPO Year | 1998 | 2000 |
Fundamental Metrics
Financial Performance| Metric | TSBK | RIGL |
|---|---|---|
| Price | $37.47 | $42.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $43.20 |
| AVG Volume (30 Days) | 16.6K | ★ 589.6K |
| Earning Date | 01-26-2026 | 11-04-2025 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | 21.93 | ★ 2698.26 |
| EPS | 3.67 | ★ 6.20 |
| Revenue | $81,618,000.00 | ★ $282,076,000.00 |
| Revenue This Year | N/A | $65.53 |
| Revenue Next Year | N/A | $0.22 |
| P/E Ratio | $10.19 | ★ $6.78 |
| Revenue Growth | 10.07 | ★ 79.13 |
| 52 Week Low | $27.51 | $14.63 |
| 52 Week High | $38.08 | $52.24 |
Technical Indicators
Market Signals| Indicator | TSBK | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 72.88 | 49.51 |
| Support Level | $36.99 | $40.52 |
| Resistance Level | $37.90 | $43.58 |
| Average True Range (ATR) | 0.79 | 2.88 |
| MACD | 0.25 | -1.04 |
| Stochastic Oscillator | 87.38 | 19.54 |
Price Performance
Historical ComparisonAbout TSBK Timberland Bancorp Inc.
Timberland Bancorp Inc is a bank holding company. It has one reportable operating segment which is defined as community banking in western Washington under the operating name Timberland Bank. The bank offers a variety of services such as checking accounts, online and mobile banking, savings accounts, home loans, consumer loans, construction loans, business rewards, cash management, small business solutions, and business checking accounts among others. It also offers loans to real estate, including residential and commercial, multi-family construction loans, one- to four-family residential loans, multi-family loans, commercial real estate loans, and land loans.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.